Researchers reported on Wednesday that blood thinners appear to lessen the death risk by up to fifty percent among hospitalized COVID-19 seriously ill patients. A team at the Mount Sinai Health System in New York reported that patients given anticoagulants (blood thinners) also thirty percent less likely to need a ventilator to help them breathe.

Blood thinners appear to reduce the risk of death by up to 50% among seriously ill, hospitalized coronavirus patients, and patients given anticoagulants also were 30% less likely to need a ventilator to help them breathe, researchers have reported https://t.co/OfqNYVjb3l

— CNN (@CNN) August 27, 2020

Their research of over 4,300 patients, also those who died frequently, had evidence of blood clots all over their bodies, although several of them had no symptoms of the problem. It is more sign of the severe and systemwide blood clotting that COVID-19 infections can cause, whereas the discoveries offer hope of countering the effect.

Therapeutic anticoagulation and prophylactic associated with reduced

morality rate

The team in the report published in the Journal of the American College of Cardiology said that compared to no anticoagulation, both therapeutic anticoagulation and prophylactic associated with reduced death rate and intubation. The study’s head, Dr. Valentin Fuster, says that is next. Fuster told CNN that an international randomized trial just started with fifteen institutions.

The team of Fluster stated that sixty percent of patients who didn’t take anticoagulants, released from the hospital, twenty-six percent of them died in the hospital, and thirteen percent still in the hospital. When patients take the drug prophylactically to avoid blood clots, seventy-five percent released alive, twenty-two percent died in the hospital, and three percent still hospitalized during the research period.

Remdesivir is the only confirm treatment for coronavirus

The researcher states that the decrease in the risk of death was similar to inpatients who got anticoagulants either to avoid blood clots or after they start showing evidence of clotting. The only authentic treatment for COVID-19 is the antiviral drug remdesivir. Doctors treating the coronavirus patient learned that steroids, definitely dexamethasone, also help COVID-19 patients recover better from the viral infections.

Trials are in progress to test therapies that deliver several types of antibodies to help patients fight off the viral infection, using plasma of people recovering from infections. Soon after the epidemic hit New York City at its peak in March, physicians started observing that their patients suffered from system-wide clotting of blood.

These blood clots blocked up kidney dialysis equipment and hurt patients’ livers, hearts, and lungs. Doctors now believe that the inflammation because of COVID-19 infection, causing the blood clotting. In the Mount Sinai research, postmortems on some of the dead patients showed that forty-two percent had blood clots, including their liver, heart, brain, and lungs.

Read Also: Pfizer & BioNTech started phase 3 trial of COVID-19 vaccine